Optic Neuropathy

My residency director, David Carey, used to say ironically, “If you step back and take a careful look, you’ll see there’s a whole patient behind that eyeball.”

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since early 2022.

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according to findings from a retrospective study.

Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation.

A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential association between prescribed semaglutide and an increased risk for nonarteritic anterior ischemic optic neuropathy.

Drugs utilized to treat systemic diseases can do harm to the eye and its neural connections.

A 53-year-old man presented to the comprehensive ophthalmology service at New England Eye Center for a second opinion of a new dark gray spot in his upper right visual field.

A deep learning system achieved an accuracy of more than 90% in distinguishing arteritic from nonarteritic anterior ischemic optic neuropathy using only color fundus images, according to a study published in JAMA Ophthalmology.

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa.